Menu

Top Stories

Published on Tuesday, November 6, 2018

Mereo BioPharma and TAP work together in clinical study

Mereo BioPharma and TAP work together in clinical study

Mereo BioPharma Group plc announced a collaboration with (and investment from) the venture philanthropy arm of the Alpha-1 Foundation, The Alpha-1 Project, Inc. (TAP) in Mereo’s MPH-966 development program.

MPH-966 is an oral neutrophil elastase inhibitor that specifically targets the neutrophil elastase which is primarily responsible for the lung degradation in Alpha-1 patients.

TAP investment was announced in Mereo’s November 5th press release, publicizing that the first Alpha-1 patient was dosed in their Phase 2 clinical study of MPH-966 (alvelestat). The study is a 12-week randomized, placebo controlled, clinical trial evaluating two doses of MPH-966 in approximately 165 patients with the ZZ or NULL genetic mutations of Alpha-1. These mutations are associated with the more severely affected patients who have very low (ZZ) or zero (NULL) alpha-1 antitrypsin levels.

“We are very pleased that the first patient has been successfully dosed in this phase 2 study in Alpha-1 Antitrypsin Deficiency. We are excited by the potential for a new oral therapeutic to improve the lives of our patients with this debilitating disease and are pleased to be supporting Mereo with this phase 2 study,” said Jean-Marc Quach, president and CEO of TAP.

The study is being conducted in the United States and Europe with top line data expected in the second half of 2019. If the results are positive, Mereo intends to seek regulatory advice on the design of a pivotal trial.

To read the full press release, please click here.

Source: Mereo BioPharma Group plc


Print

Study: Music therapy improves COPD symptoms

Friday, January 15, 2016
A new study has found that patients with chronic obstructive pulmonary disease (COPD) and other chronic respiratory conditions showed signs of improvement in symptoms, psychological well-being, and quality of life when exposed to music therapy in...
Divider

Foundation congratulates Califf for Senate Committee's unanimous approval of his nomination as FDA commissioner

Tuesday, January 12, 2016
The Alpha-1 Foundation on Tuesday congratulated Robert Califf, MD, on the Senate Health, Education, Labor, and Pensions (HELP) Committee’s unanimous approval of his nomination to be the U.S. Food and Drug Administration (FDA)...
Divider

Alpha-1 Foundation scientific, clinical directors edit book on Alpha-1 for clinicians and researchers

Tuesday, January 12, 2016
A new book edited by two prominent Alpha-1 experts explores the causes and symptoms of the condition, and highlights the role of healthcare organizations in providing treatment. Geared toward pulmonary clinicians and scientists, “Alpha-1...
Divider

Arrowhead’s ARC-AAT granted EMA orphan drug designation

Monday, January 11, 2016
PASADENA, Calif. — Arrowhead Research Corporation, a biopharmaceutical company that is developing targeted gene therapies, today announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation to ARC-AAT, a treatment...
Divider

Skyrocketing drug prices leave cures out of reach for some patients

Thursday, January 7, 2016
Sophisticated drugs are opening the door, scientists say, to an era of "precision medicine." They're also ushering in an age of astronomical prices. New cancer drugs are routinely priced at more than $100,000 a year — nearly twice the...
Divider

FDA approved 21 new drugs to treat rare "orphan" diseases in 2015

Tuesday, January 5, 2016
The U.S. Food and Drug Administration (FDA) announced this week that it approved 21 new drugs to treat rare or “orphan” diseases in 2015, nearly half (47 percent) of all novel new drugs that were approved for the year. This...
Divider

Why do some Alphas develop liver disease?

Tuesday, December 15, 2015
In Alphas with the ZZ genotype, most of the alpha-1 protein made in the liver misfolds and gets trapped in the liver cells instead of moving normally into the bloodstream. Because of the ZZ gene mutation, the misfolded proteins link to one...
Divider

Webinar will answer questions about natural history studies (like Alpha-1 Adult Liver Study)

Wednesday, December 9, 2015
Alphas and others with rare diseases are invited to join a free webinar on natural history studies for rare diseases at 11 a.m. EST on Thursday, Dec. 10. "If there is one area in which the rare disease patient can make a contribution to rare...
Divider

Alpha-1-To-One magazine Winter issue in your mail now

Thursday, December 3, 2015
The Winter 2015 issue of Alpha-1-To-One magazine is in the mail to some 27,000 people with free subscriptions and is now available online. Read the cover story, "A New Beginning: Frank Willersinn gets second chance at life and makes the most...
Divider

November is Alpha-1 Awareness Month

Monday, November 2, 2015
MIAMI, Nov. 2, 2015 – The Alpha-1 Foundation is marking Alpha-1 Awareness Month, designed to increase knowledge about Alpha-1 Antitrypsin Deficiency (Alpha-1). Throughout the month of November, people with Alpha-1 will hold educational...
Divider

Buyer beware: Alphas urged to avoid companies advertising unproven stem cell "treatments" that can cost you a fortune

Wednesday, October 28, 2015
This is a note from the Alpha-1 Foundation explaining why Alphas should be wary of claims advertised on the Internet by companies claiming benefits from unproven stem cell and other cell-based "therapies." What are stem cells? Stem cells are the...
Divider

FDA launches learning tool on how to bring new drugs to market

Thursday, October 22, 2015
The U.S. Food and Drug Administration (FDA) has launched a new learning tool designed to help patients, patient advocacy groups, health professionals, small businesses, pharmaceutical and clinical innovators learn more about the drug regulatory...
Divider
123456789

Article Search

Enter keywords in text box and click Search button for results.